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REDUCTION IN SERUM MYELOMA (M) PARAPROTEIN AFTER CYCLO-
PHOSPHAMIDE (CY) MOBILIZATION PREDICTS FOR IMPROVED SUR-
VIVAL AFTER SINGLE-AGENT MELPHALAN (MEL)–BASED AUTOLO-
GOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT)
Aggarwal, C., Shah, H.R., Salzman, D.E., Tilden, A.B.,
Vaughan, W.P. Bone Marrow Transplantation Program, University of
Alabama at Birmingham, Birmingham, AL.
We reviewed survival after single agent MEL/AHSCT per-
formed at University of Alabama at Birmingham for 60 consecutive
myeloma patients between April 2000 and May 2004 using Cy plus
G-CSF for HSC mobilization. The Cy dose was 2.5 g/m2, fol-
lowed by subcutaneous G-CSF 10–16 g/kg daily beginning the
next day and continued until 4  106/kg CD34 cells could be
collected by apheresis. Four patients (7%) required additional
mobilization with either the same or escalated dose to achieve
target. There was minimal morbidity and no mortality from mo-
bilization and only 1 case of AHSCT-related mortality. Thirty-one
patients (51%) received MEL/AHSCT within 8 weeks of mobili-
zation; the rest had a delay of 9–72 weeks (median, 16 weeks) due
to personal preference, physical recovery, dramatic response to Cy,
or further therapy. The cumulative probability of overall survival
(OS) from diagnosis for these 60 patients is 68% at 8 years longest
follow-up (median, 21 months). Quantitative serum M protein and
IFE were determined on these patients before and after Cy and
again before and after AHSCT. Cy response (CyR), deﬁned as any
decrease in the M protein or disappearance of the positive IFE
(median, 18%; range, 1%-100%), occurred in 40 patients (67%);
Cy nonresponse (CyNR) (median increase, 23%; range, 2%-
100%) occurred in 14 patients (23%), and 6 patients (10%) were
not evaluable due to insufﬁcient data. Median age at AHSCT for
CyR and CyNR was 58.5 and 58 years, respectively (ranges, 33–74
years and 47–66 years). Both groups had a 4-month median dura-
tion of prior chemotherapy. The OS from AHSCT for CyR is 92%
at 31 months longest follow-up (median, 11 months) versus 61%
for CyNR at 42 months longest follow-up (median, 7 months)
(log-rank test, P  .035). ASBMT criteria were used for risk
classiﬁcation. There were 28 (70%) low-risk (LR) CyR patients
and 6 (43%) LR CyNR patients. The larger number of LR patients
in the CyR group was not statistically signiﬁcant (2 test, P  .07)
and the OS of LR patients as a whole was not better than that of
the HR patients (log-rank test, P .76). Thus the difference in OS
between CyR and CyNR cannot be attributed to risk status alone.
Considering that risk status might still be a confounding factor, we
calculated observed versus expected mortality for risk factor subsets
and recombined the groups. Despite this adjustment, the superior
OS for the CyR group remained signiﬁcant (P  .047). There was
no signiﬁcant difference in progression-free survival or freedom
from relapse between the 2 groups. Conclusions: We conclude
that disease response to Cy mobilization, as measured by decrease
in serum M protein, predicts improved survival after single-agent
MEL/AHSCT in patients with myeloma.
231
FLOW CYTOMETRIC MONITORING OF NORMAL PLASMA CELLS AFTER
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MY-
ELOMA (MM)
Liu, H.1, Yuan, C.M.2, Braylan, R.2, Wingard, J.R.1, Moreb, J.S.1
1University of Florida, Department of Medicine, Gainesville, FL; 2Uni-
versity of Florida, Department of Pathology, Gainesville, FL.
Persistence of abnormal neoplastic plasma cells (APLs) detect-
able by ﬂow cytometry at  3 months after autografting for MM
has been reported to predict early disease progression. In this
study, we retrospectively reviewed the ﬂow cytometric data from
bone marrow aspirates from MM patients before and after autol-
ogous stem cell transplantation (ASCT). CD38 expression was
used to identify plasma cells, and CD19/CD45/CD56 expression
was used to distinguish normal plasma cells (NPCs) from APCs. A
minimum of 30 events that satisﬁed the gating strategy were
required. Conventional response criteria (Blade criteria) and sur-
vival data were also collected. A total of 34 patients treated with the
same conditioning regimen were screened between May 2001 and
April 2004, but only 26 of these patients had adequate ﬂow cyto-
metric data before and after ASCT, whereas 31 patients had data
available between 8 weeks and 12 months after ASCT. Median
follow-up from ASCT was 12 months. NPCs and APCs were
present in 42% (11 of 26) and 54% (14 of 26) of patients after ASCT
compared to 12.5% and 67% before ASCT. There were 14 patients
in CR/VGPR after ASCT, compared to only 6 before ASCT. No
correlation was found between the presence of APCs or NPCs and
response status, PFS, or OS. However, of the 15 patients with an
APC:NPC ratio  1, 67% had CR/VGPR, and of the 11 patients
with an APC:NPC ratio 1, 36% hadCR/VGPR.Using themethod
of Kaplan and Meier, the median PFS for patients with an APC:NPC
ratio&le: 1 has not been reached, whereas themedian PFS for the rest
of patients was 18 months (P  .0896). OS has not been reached for
either group. In conclusion, recovery of NPCs after ASCT is seen in
a signiﬁcant number of patients and may serve as another predictor of
better PFS in MM patients.
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A SINGLE INSTITUTION LONG-TERM EXPERIENCE USING AUTOLO-
GOUS STEM CELL TRANSPLANTATION FOR THE MANAGEMENT OF
HODGKIN’S LYMPHOMA
Skikne, B., Thudi, N., Deauna-Limayo, D., Ganguly, S.,
Bodensteiner, D., Devine, C., Cook, J.D. Kansas University Medical
Center, Kansas City, KS.
Patients with stage III-IV Hodgkin’s lymphoma (HL) or with
bulky stage I/II disease have a relapse rate of 30%-40% after
primary treatment. High-dose chemotherapy with stem cell trans-
plantation (Tx) is a treatment option after relapse or in those with
primary induction failure. In the present study, we examined long-
term outcomes in 45 relapsed/primary induction failure HL pa-
tients undergoing autologous peripheral stem cell (25 patients),
bone marrow (17) or combination (3) Tx between 1985 and De-
cember 2003. The median age was 32 years (range, 16–64 years);
38 patients had nodular sclerosing HL;, 17 had stage I/II disease,
13 had stage III disease, and 15 had stage IV disease; and 33 had B
symptoms at diagnosis. Twenty patients were previously treated
with 1–2 prior regimens, while 25 had  3 treatment regimens.
Sixteen patients had sensitive disease to salvage therapy prior to
Tx, 27 had resistance to salvage therapy, and 2 did not undergo
pre-Tx salvage therapy. Five patients had primary resistant disease,
33 had relapsed disease, and 7 were in CR at the time of Tx. CBV
was used in 30 patients, BEAM was used in 9, and 5 received
CY/TBI-based regimens. Five patients (11%) had early mortality
( 100 days) directly attributable to the procedure; 4 of these were
cardiac related, and 1 was due to infection. The overall response
was 93% with CR achieved in 28 (62%) and PR in 14 (31%). The
median OS was 5.5 years, and the median DFS was 1 year, with a
5-year DFS in 26%. For patients achieving CR after Tx, 74%
remain alive at  10 years, and the median survival has not been
reached. However, the median PFS was 1.6 years in patients
achieving CR after Tx and 9.2 months in those with an incomplete
response after Tx (P  .05). Seventeen patients are alive, 2 are lost
to follow-up, and 21 have died. Fourteen (31%) died from disease
progression (31%), 2 (4%) died from MDS/AML occurring after
32 and 66 months, 2 (4%) died of late-occurring infections, 2 (4%)
died from respiratory failure, and 1 (2%) died from late cardiac
failure. OS and DFS did not differ based on peripheral stem cell
versus bone marrow Tx, B symptoms at diagnosis, sex differences,
age  20 years versus  20 years, or high-dose therapy regimens,
but a difference in OS (P  .04) and DFS (P  .03) was seen in
patients transplanted in CR versus those transplanted in active
disease. Patients with sensitive disease to salvage therapy before Tx
did show a trend toward improved OS and DFS, but this was not
signiﬁcant. High-dose chemotherapy and autologous stem cell Tx
can lead to prolonged DFS in 25%-35% of patients.
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